{"id":3317,"date":"2021-03-03T23:30:00","date_gmt":"2021-03-03T23:30:00","guid":{"rendered":"http:\/\/staging.grindeks.eu\/in-2020-the-grindeks-group-has-achieved-the-historically-sharpest-increase-in-turnover-and-profit\/"},"modified":"2022-07-04T23:32:39","modified_gmt":"2022-07-04T23:32:39","slug":"in-2020-the-grindeks-group-has-achieved-the-historically-sharpest-increase-in-turnover-and-profit","status":"publish","type":"post","link":"https:\/\/grindeks.com\/lv\/in-2020-the-grindeks-group-has-achieved-the-historically-sharpest-increase-in-turnover-and-profit\/","title":{"rendered":"2020. gad\u0101 Grindeks koncerns sasniedzis v\u0113sturiski strauj\u0101ko apgroz\u012bjuma un pe\u013c\u0146as k\u0101pumu"},"content":{"rendered":"\n

2020. gad\u0101 Grindeks koncerns sasniedzis v\u0113sturiski strauj\u0101ko apgroz\u012bjuma un pe\u013c\u0146as k\u0101pumu. Koncerna konsolid\u0113tie, provizoriskie finan\u0161u dati liecina, ka 2020. gad\u0101 Grindeks koncerna apgroz\u012bjums sasniedza 187,0 milj. eiro, kas ir par 45,6 milj. eiro vai 32% vair\u0101k nek\u0101 2019. gad\u0101. 2020. gada koncerna pe\u013c\u0146a bija 19,0 milj. eiro, kas ir par 5,6 milj. eiro vai par 42% vair\u0101k nek\u0101 2019. gad\u0101.<\/p>\n\n\n\n

2020. gad\u0101 Grindeks koncerns stiprin\u0101ja savas poz\u012bcijas glob\u0101l\u0101 farm\u0101cijas tirg\u016b un sara\u017eoto produkciju eksport\u0113ja uz 93 valst\u012bm kop\u0101 par 176,1 milj. eiro. Savus produktus koncerns farm\u0101cijas tirg\u016b pied\u0101v\u0101 ar diviem z\u012bmoliem \u2013 Grindeks un Kalceks.<\/p>\n\n\n\n

AS Grindeks valdes priek\u0161s\u0113d\u0113t\u0101js Dr. chem. Juris Hme\u013c\u0146ickis p\u0113rno gadu raksturo k\u0101 noz\u012bm\u012bgu p\u0101rmai\u0146u un sasniegumu gadu: \u201c2020. gad\u0101 m\u0113s s\u0101k\u0101m ieviest jaunu Biznesa strat\u0113\u0123iju l\u012bdz 2025. gadam un sp\u0113r\u0101m \u013coti svar\u012bgus so\u013cus, lai main\u012btu biznesa organiz\u0101ciju, darba kult\u016bru un Grindeks z\u012bmolu. Turkl\u0101t viss notika sare\u017e\u0123\u012btaj\u0101, glob\u0101laj\u0101 situ\u0101cij\u0101, ko ietekm\u0113ja Covid-19 pand\u0113mija. Koncerna komandas salied\u0113tais darbs un sp\u0113ja piel\u0101goties negaid\u012btiem apst\u0101k\u013ciem pal\u012bdz\u0113ja sasniegt l\u012bdz \u0161im augst\u0101kos apgroz\u012bjuma un pe\u013c\u0146as r\u0101d\u012bt\u0101jus. M\u016bsu m\u0113r\u0137i 2021. gadam ar\u012b ir ambiciozi, un l\u012bdz \u0161im paveiktais dod dro\u0161u p\u0101rliec\u012bbu par Grindeks koncerna n\u0101kotnes iesp\u0113j\u0101m.\u201d<\/p>\n\n\n\n

2021. gad\u0101 Grindeks koncerns pl\u0101no apgroz\u012bjumu palielin\u0101t par 19%.<\/p>\n\n\n\n

Glob\u0101la ekspansija jaunos un poz\u012bciju nostiprin\u0101\u0161ana eso\u0161ajos tirgos<\/strong><\/p>\n\n\n\n

Koncerna gatavo z\u0101\u013cu p\u0101rdo\u0161anas apjoms 2020. gad\u0101 bija 173,6 milj. eiro un ir palielin\u0101jies, sal\u012bdzinot ar 2019. gadu, par 41,5 milj. eiro vai par 31%.<\/p>\n\n\n\n

P\u0101rdo\u0161anas apjoms Krievij\u0101, p\u0101r\u0113j\u0101s NVS valst\u012bs un Gruzij\u0101 2020. gad\u0101 veidoja 87,7 milj. eiro, kas ir par 9,8 milj. eiro vai par 13% vair\u0101k nek\u0101 2019. gad\u0101. Sal\u012bdzinot ar 2019. gadu, 2020. gad\u0101 noz\u012bm\u012bgs p\u0101rdo\u0161anas apjoma pieaugums sasniegts \u2013 Uzbekist\u0101n\u0101 par 39%, Azerbaid\u017e\u0101n\u0101 par 22%, Kirgizst\u0101n\u0101 par 16% un Kazahst\u0101n\u0101 par 15%.<\/p>\n\n\n\n

Koncerna gatavo z\u0101\u013cu p\u0101rdo\u0161anas apjoms Eiropas Savien\u012bbas valst\u012bs, Lielbrit\u0101nij\u0101 un Norv\u0113\u0123ij\u0101 2020. gad\u0101 sasniedza 76,9 milj. eiro, kas ir par 26,1 milj. eiro vai par 52% vair\u0101k nek\u0101 2019. gad\u0101. P\u0101rdo\u0161anas apjoms 2020. gad\u0101, sal\u012bdzinot ar 2019. gadu, Be\u013c\u0123ij\u0101 palielin\u0101j\u0101s 751 reizes, Sp\u0101nij\u0101 81 reizes, D\u0101nij\u0101 un N\u012bderland\u0113 5 reizes, Somij\u0101 3 reizes, Latvij\u0101 par 37%, Lielbrit\u0101nij\u0101 par 29%, Igaunij\u0101 par 20%, bet V\u0101cij\u0101 par 10%. Augstie p\u0101rdo\u0161anas rezult\u0101ti Be\u013c\u0123ij\u0101 un Sp\u0101nij\u0101 sasniegti, pateicoties Grindeks meitas uz\u0146\u0113muma Kalceks intens\u012bvajam darbam un biznesa att\u012bst\u012bbai Eiropas Savien\u012bbas valst\u012bs.<\/p>\n\n\n\n

2020. gad\u0101 akt\u012bvo farmaceitisko vielu p\u0101rdo\u0161anas apjoms sasniedza 12,5 milj. eiro, kas ir par 3,9 milj. eiro vai par 46% vair\u0101k nek\u0101 2019. gad\u0101. Liel\u0101kais Grindeks akt\u012bvo farmaceitisko vielu eksports tika veikts uz ES valst\u012bm, ASV, Jap\u0101nu un Kan\u0101du.<\/p>\n\n\n\n

Koncerna strat\u0113\u0123iskais m\u0113r\u0137is ir darb\u012bbas papla\u0161in\u0101\u0161ana Eiropas Savien\u012bbas valst\u012bs, ASV, Jap\u0101n\u0101, Dienvidkorej\u0101, Austr\u0101lij\u0101 un Jaunz\u0113land\u0113.<\/p>\n\n\n\n

Covid-19 \u0161\u0137\u0113r\u0161\u013ci rada jaunas iesp\u0113jas<\/strong><\/p>\n\n\n\n

L\u012bdz\u012bgi k\u0101 citi uz\u0146\u0113mumi ar\u012b Grindeks koncerns 2020. gad\u0101 Covid-19 v\u012brusa izplat\u012bbas ietekm\u0113 p\u0101rk\u0101rtoja savu saimniecisko darb\u012bbu. Lai p\u0101rvar\u0113tu Covid-19 izrais\u012btos darb\u012bbas \u0161\u0137\u0113r\u0161\u013cus, koncerns noteica tr\u012bs priorit\u0101tes: darbinieku vesel\u012bbas aizsardz\u012bba un dro\u0161\u012bba, pacientu vesel\u012bbas vajadz\u012bbu nodro\u0161in\u0101\u0161ana un saimniecisk\u0101s darb\u012bbas nep\u0101rtraukt\u012bba.
Covid-19 pand\u0113mija ir main\u012bjusi pacientu vajadz\u012bbas, t\u0101p\u0113c ra\u017eo\u0161ana tika p\u0101rk\u0101rtota t\u0101, lai var\u0113tu apmierin\u0101t augo\u0161o piepras\u012bjumu un ra\u017eot vair\u0101k. Sp\u0113ja darboties \u0101rk\u0101rtas apst\u0101k\u013cos un operat\u012bvi rea\u0123\u0113t uz piepras\u012bjuma pieaugumu veicin\u0101ja darb\u012bbu jaunos tirgos \u2013 Sp\u0101nij\u0101, Be\u013c\u0123ij\u0101, It\u0101lij\u0101, D\u0101nij\u0101, Lielbrit\u0101nij\u0101 un cit\u0101s valst\u012bs.<\/p>\n\n\n\n

Vesel\u012bbas risin\u0101jumi m\u016bsdienu pras\u012bb\u0101m un dinamiskajam dz\u012bvesveidam<\/strong><\/p>\n\n\n\n

Biznesa strat\u0113\u0123ija l\u012bdz 2025. gadam paredz b\u016btiski papla\u0161in\u0101t Grindeks produktu kl\u0101stu ar m\u016bsdien\u012bgiem medikamentiem sirds un asinsvadu, centr\u0101l\u0101s nervu sist\u0113mas, onkolo\u0123isko saslim\u0161anu un diab\u0113ta \u0101rst\u0113\u0161anai, k\u0101 ar\u012b ar Kalceks medikamentiem slimn\u012bcu segmentam. Izstr\u0101d\u0113 ir 51 jauns Grindeks un 35 jauni Kalceks medikamenti.<\/p>\n\n\n\n

Grindeks past\u0101v\u012bgi ra\u017eo 25 akt\u012bv\u0101s farmaceitisk\u0101s vielas un ir gadiem ilgi uzkr\u0101jis zin\u0101\u0161anas akt\u012bvo farmaceitisko vielu biznesa jom\u0101. T\u0101 ir koncerna unikalit\u0101te un konkurences priek\u0161roc\u012bba. \u0160\u012b segmenta att\u012bst\u012bba paaugstina koncerna neatkar\u012bbu no izejvielu ra\u017eot\u0101jiem, kas perspekt\u012bv\u0101 b\u016bs Latvijas un pat Eiropas Savien\u012bbas l\u012bme\u0146a ieguvums pacientu z\u0101\u013cu pieejam\u012bb\u0101. Izstr\u0101d\u0113 ir 21 jauna akt\u012bv\u0101 farmaceitisk\u0101 viela.<\/p>\n\n\n\n

Meitas uz\u0146\u0113muma Kalceks att\u012bst\u012bba<\/strong><\/p>\n\n\n\n

2020. gad\u0101 Grindeks meitas uz\u0146\u0113mums AS Kalceks, kura specializ\u0101cija ir medikamenti slimn\u012bcu segmentam, sasniedza \u013coti strauju p\u0101rdo\u0161anas apjoma pieaugumu, ko pan\u0101ca, k\u0101pinot eksporta valstu skaitu un ievie\u0161ot jaunus produktus. Kalceks produkti 2020. gad\u0101 tika p\u0101rdoti 40,7 milj. eiro apjom\u0101, kas ir par 24,0 milj. eiro vai 2,4 reizes vair\u0101k nek\u0101 2019. gad\u0101. Kalceks medikamenti 2020. gad\u0101 tika eksport\u0113ti uz 62 valst\u012bm, un galvenie noieta tirgi bija Sp\u0101nija, Be\u013c\u0123ija, Izra\u0113la, Lielbrit\u0101nija un Francija. 2020. gad\u0101 AS Kalceks iesniedza re\u0123istr\u0101cijai Eiropas Savien\u012bb\u0101 8 jaunus produktus.<\/p>\n\n\n\n

Ra\u017eo\u0161anas infrastrukt\u016bras papla\u0161in\u0101\u0161ana<\/strong><\/p>\n\n\n\n

Grindeks ir uzs\u0101cis izstr\u0101d\u0101t projektu jaunas farmaceitisk\u0101s r\u016bpn\u012bcas b\u016bvniec\u012bbai Latvij\u0101. Jaun\u0101 r\u016bpn\u012bca tiks b\u016bv\u0113ta vair\u0101kos posmos un ietvers komplic\u0113tus akt\u012bvo farmaceitisko vielu ra\u017eo\u0161anas procesus un daudzveid\u012bgas tehnolo\u0123isk\u0101s iek\u0101rtas. T\u0101 b\u016bs liel\u0101k\u0101 farmaceitisk\u0101 ra\u017eotne Baltijas re\u0123ion\u0101 ar automatiz\u0113tiem un energoefekt\u012bviem tehniskajiem risin\u0101jumiem.
Ra\u017eo\u0161an\u0101 tiks ieviestas z\u0101\u013cu formas, kuras \u0161obr\u012bd Latvij\u0101 Grindeks nera\u017eo: ampulas, flakonus, liofiliz\u0113tus flakonus, acu pilienus un antibiotikas. Jaunaj\u0101 ra\u017eotn\u0113, kas atrad\u012bsies R\u012bg\u0101, Asotes iel\u0101 2a, tiks izveidotas 800-1000 jaunas darbavietas.<\/p>\n\n\n\n

Sekm\u012bgi apstiprinot b\u016bvprojektu, jaun\u0101s r\u016bpn\u012bcas celtniec\u012bbu pl\u0101nots uzs\u0101kt 2022. gad\u0101.<\/p>\n\n\n\n

AS Grindeks padomes priek\u0161s\u0113d\u0113t\u0101js Kirovs Lipmans atzin\u012bgi nov\u0113rt\u0113 Grindeks koncerna darb\u012bbas rezult\u0101tus 2020. gad\u0101: \u201cLai gan apst\u0101k\u013ci pag\u0101ju\u0161\u0101 gad\u0101 nebija vienk\u0101r\u0161i un viegli, Grindeks koncerns ir palielin\u0101jis savu konkur\u0113tsp\u0113ju farm\u0101cijas glob\u0101laj\u0101 ar\u0113n\u0101, pied\u0101v\u0101jot efekt\u012bvas z\u0101les un vesel\u012bbai nepiecie\u0161amus risin\u0101jumus. Biznesa strat\u0113\u0123ija 2025. gadam \u012bstenojas un par\u0101da teicamus rezult\u0101tus. V\u0113los pateikties par paveikto darbiniekiem un sadarb\u012bbas partneriem!\u201d<\/p>\n\n\n\n

<\/h3>\n","protected":false},"excerpt":{"rendered":"

2020. gad\u0101 Grindeks koncerns sasniedzis v\u0113sturiski strauj\u0101ko apgroz\u012bjuma un pe\u013c\u0146as k\u0101pumu. Koncerna konsolid\u0113tie, provizoriskie finan\u0161u dati liecina, ka 2020. gad\u0101 Grindeks koncerna apgroz\u012bjums sasniedza 187,0…<\/p>\n","protected":false},"author":3,"featured_media":3314,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-3317","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-jaunums"],"acf":[],"_links":{"self":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/3317","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/comments?post=3317"}],"version-history":[{"count":0,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/3317\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/media\/3314"}],"wp:attachment":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/media?parent=3317"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/categories?post=3317"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/tags?post=3317"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}